Based on the pathogenesis of PAP, several new therapeutic approaches for treating autoimmune PAP targeting GM-CSF are in clinical trials, including plasmapheresis [128], GM-CSF administration [129, 130], and rituximab [131, 132]. The gene discussed is CSF2; the disease is pulmonary alveolar proteinosis.